<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Huang B</submitter><funding>NIDDK NIH HHS</funding><funding>NIAMS NIH HHS</funding><pagination>121850</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12433583</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>293</volume><pubmed_abstract>As a surging public health crisis, obesity and overweight predispose individuals to various severe comorbidities contributed by the accompanying chronic inflammation. However, few options exist for tackling chronic inflammation in obesity or inhibiting depot-specific adiposity. Here, we report that polycationic polyamidoamine (PAMAM) treatment can improve both aspects of obesity. With the discovery that the plasma cell-free RNA (cfRNA) level is elevated in obese subjects, we applied the cationic PAMAM generation 3 (P-G3) scavenger to treat diet-induced obese (DIO) mice. Intraperitoneal delivery of P-G3 alleviated the chronic inflammation in DIO mice and reduced their body weight, resulting in improved metabolic functions. To further enhance the applicability of P-G3, we complexed P-G3 with</pubmed_abstract><journal>Biomaterials</journal><pubmed_title>Polycationic PAMAM ameliorates obesity-associated chronic inflammation and focal adiposity.</pubmed_title><pmcid>PMC12433583</pmcid><funding_grant_id>R01 AR073935</funding_grant_id><funding_grant_id>P30 DK026687</funding_grant_id><pubmed_authors>Wan Q</pubmed_authors><pubmed_authors>Yu L</pubmed_authors><pubmed_authors>Li T</pubmed_authors><pubmed_authors>Calhoun C</pubmed_authors><pubmed_authors>Du W</pubmed_authors><pubmed_authors>Leong KW</pubmed_authors><pubmed_authors>Huang B</pubmed_authors><pubmed_authors>Qiang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Polycationic PAMAM ameliorates obesity-associated chronic inflammation and focal adiposity.</name><description>As a surging public health crisis, obesity and overweight predispose individuals to various severe comorbidities contributed by the accompanying chronic inflammation. However, few options exist for tackling chronic inflammation in obesity or inhibiting depot-specific adiposity. Here, we report that polycationic polyamidoamine (PAMAM) treatment can improve both aspects of obesity. With the discovery that the plasma cell-free RNA (cfRNA) level is elevated in obese subjects, we applied the cationic PAMAM generation 3 (P-G3) scavenger to treat diet-induced obese (DIO) mice. Intraperitoneal delivery of P-G3 alleviated the chronic inflammation in DIO mice and reduced their body weight, resulting in improved metabolic functions. To further enhance the applicability of P-G3, we complexed P-G3 with</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2026-06-03T03:00:42.005Z</modification><creation>2026-04-23T03:13:36.242Z</creation></dates><accession>S-EPMC12433583</accession><cross_references><pubmed>36450630</pubmed><doi>10.1016/j.biomaterials.2022.121850</doi></cross_references></HashMap>